Fortrea Holdings Valuation
Is FTRE1 * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FTRE1 * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FTRE1 * (MX$435.3) is trading below our estimate of fair value (MX$1685.06)
Significantly Below Fair Value: FTRE1 * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FTRE1 *?
Key metric: As FTRE1 * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is FTRE1 *'s PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | US$2.98b |
| Market Cap | US$1.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 112x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FTRE1 *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.9x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.6b |
INDGN Indegene | 6x | 11.9% | ₹161.5b |
603108 Shanghai Runda Medical Technology | 1.4x | n/a | CN¥11.5b |
GUBRA Gubra | 46.9x | n/a | DKK 10.5b |
FTRE1 * Fortrea Holdings | 0.6x | 2.4% | Mex$1.9b |
Price-To-Sales vs Peers: FTRE1 * is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (13.9x).
Price to Sales Ratio vs Industry
How does FTRE1 *'s PS Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: FTRE1 * is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is FTRE1 *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FTRE1 *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Incyte
US$13.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
INCY *
US$1,486.00
7D
0%
1Y
n/a